Eisai slashes U.K. R&D jobs in 'global' restructuring

Japan's Eisai is slashing 20 R&D jobs and eliminating some 30 consultants contracts in the UK as part of a global R&D restructuring, according to a local spokesperson for the company. "That part of the business is being restructured globally, and jobs are at risk," the spokesperson told the Welwyn Hatfield Times. "We will support the employees whose jobs are being put at risk by this reorganization." More

Suggested Articles

Biogen stunned the biotech world Tuesday when it said it would file aducanumab for approval. Now that the dust has settled, what are analysts saying?

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.